Summary of Clinical Use

Having completed Phase 3 clinical trials for various forms of psoriasis, guselkumab was approved in 2017 for patients with moderate to severe plaque psoriasis. It was subsequently investigated for efficacy in other autoimmune conditions.

Mechanism Of Action and Pharmacodynamic Effects

The cytokine IL23 plays an important role in modulating the immune system. Abberant expression of IL23 has been implicated in the pathogenesis of autoimmune diseases such as psoriasis [2] and arthritis [4]. Guselkumab neutralises circulating IL23 by binding the IL23A (p19) subunit, and thereby reduces pathological disease symptoms.

Clinical Trials
Clinical Trial ID	Title	Type	Source	Comment	References
NCT03466411	A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease	Phase 2/Phase 3 Interventional	Janssen Research & Development, LLC		5
NCT06663332	A Long-term Extension (LTE) Study of Guselkumab in Pediatric Participants	Phase 3 Interventional	Janssen Research & Development, LLC

External links

For extended ADME data see the following: Electronic Medicines Compendium (eMC) Drugs.com European Medicines Agency (EMA)